The concept of "cough hypersensitivity syndrome" introduced by Irwin et al. (2006) suggests that chronic cough results from heightened sensitivity of the cough reflex. This theory supports behavioral interventions aimed at retraining the patient's response to cough stimuli.

A key study by Vertigan et al. (2006) provided initial evidence for BCST’s effectiveness, showing significant improvements in cough frequency and quality of life in a randomized controlled trial.

Recent clinical trials have reinforced the initial findings. Chamberlain-Mitchell et al. (2017) conducted an RCT that demonstrated a significant reduction in cough frequency and severity with BCST compared to supportive therapy. Another trial by Ryan et al. (2012) reported similar outcomes, with reduced cough reflex sensitivity and improved well-being.

Recent studies led by Dr. Laurie Slovarp explored novel treatments called cough desensitization treatment (CDT), which combines BCST with exposure to a cough stimulant (capsaicin). In a pilot clinical trial, 75% of CDT participants showed improvement, highlighting the therapy’s potential.

Success Rates and Outcomes

Quantitative analyses from multiple studies provide compelling evidence of BCST’s success rates. A systematic review by Chamberlain-Mitchell et al. (2019) concluded that BCST significantly reduces cough frequency, with success rates ranging from 50% to 70%. The improvements were sustained over long-term follow-ups, indicating lasting benefits. Vertigan et al. (2007) reported up to 80% of patients with refractory chronic cough experienced meaningful improvements after BCST and the methods pioneered by Dr. Slovarp et al. showed up to 75% efficacy in participating patients. 

Essentially, BCST significantly reduces cough sensitivity in about 70% of patients and a large proportion of those patients have full or near-full resolution of their cough – resulting in what is essentially remission of their cough condition.

The Hyfe Mind